Valentin Wiedling, Co-Founder and Chief Development Officer of USIL Therapeutics, discusses the gap in Europe’s radiological preparedness and the development of a dual-format treatment for radiological threats. The treatment, designed for both battlefield and hospital use, aims to address the lack of funding and interest in this field, which was previously considered a Cold War subject.
According to Wiedling, the lack of funding and interest in radiological threats led to a significant gap in Europe’s preparedness. After the Cold War, the topic went quiet for thirty years, and governments and private investors shifted their attention elsewhere. However, recent events, such as the war in Ukraine and the strikes on Iranian nuclear sites, have brought the topic back to the forefront.
The current state of radiological preparedness in Europe is alarming, with most countries having close to nothing in terms of treatment options. This is largely due to the lack of investment in this field over the past few decades. USIL Therapeutics is working to change this with the development of its dual-format treatment, UT-241 and UT-242.
Related: Common Cybersecurity Mistakes Startups Make (And How to Avoid Them)
UT-241 is an autoinjector, similar to an EpiPen, that can be used by individuals with no training or special equipment. It is intended for use by soldiers, first responders, and civil protection units working at the scene. UT-242, on the other hand, is an intravenous version for hospital use, administered by doctors once patients have been brought in.
USIL Therapeutics has received a €5.2M EU grant to support the development of its treatment. They plan to file for approval with regulatory bodies in Europe, the United States, and Japan by the end of 2027, with market entry expected in 2028/29. Between now and then, the focus will be on completing the necessary studies and preparations required by regulators, as well as securing funding to support these efforts.
Europe has been caught off guard, with limited treatment options available, highlighting the importance of investing in this field. By developing effective treatments, such as the one being worked on by USIL Therapeutics, it is possible to better protect individuals and communities from the risks associated with radiological threats.
Related: Why WalkMe Is a Top Choice Among Digital Adoption Platforms in 2025
The company will need to carefully consider the regulatory requirements for its treatment. With the support of the EU grant and a clear plan in place, USIL Therapeutics is well-positioned to bring its treatment to market and address the significant gap in Europe’s radiological preparedness.
Once approved, the treatment is expected to have a significant impact on the way radiological threats are addressed in Europe. By providing an effective treatment option, USIL Therapeutics can help reduce the risks associated with radiological exposure and improve outcomes for those affected.
USIL Therapeutics’ development of a dual-format treatment is a significant step forward in addressing the gap in Europe’s radiological preparedness. The company’s efforts to secure funding and regulatory approval are critical to bringing this treatment to market and protecting individuals and communities from radiological threats.